This drugmaker is developing breakthroughs like an 'EpiPen for heart attacks.' The market has yet to give it credit

This drugmaker is developing breakthroughs like an 'EpiPen for heart attacks.' The market has yet to give it credit

The key to its growth are a non-opioid pain reliever, a potential blockbuster lupus treatment and a drug that has been dubbed an "EpiPen for heart attacks."

This drugmaker is developing breakthroughs like an ‘EpiPen for heart attacks.’ The market has yet to give it credit

Viatris’ improving sales trends and margins combined with meaningful development opportunities could help boost its valuation multiple. Viatris combines stable cash flow from established drugs with a lower-risk development strategy to provide steadier earnings growth with less downside for investors. The company’s pipeline is anchored by three major opportunities in diverse therapeutic areas, all of which could meaningfully accelerate long-term …